Dr. Reddy's Laboratories Increases Sales but Misses Estimates on Earnings
Dr. Reddy's Laboratories (NYS: RDY) reported earnings on Aug. 30. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q1), Dr. Reddy's Laboratories missed estimates on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share was unchanged.
Gross margins dropped, operating margins improved, net margins shrank.
Dr. Reddy's Laboratories logged revenue of $456.7 million. The three analysts polled by S&P Capital IQ predicted a top line of $469.0 million on the same basis. GAAP reported sales were 3.2% higher than the prior-year quarter's $442.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.35. The one earnings estimate compiled by S&P Capital IQ predicted $0.41 per share. GAAP EPS of $0.35 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 53.3%, 10 basis points worse than the prior-year quarter. Operating margin was 15.4%, 160 basis points better than the prior-year quarter. Net margin was 13.2%, 10 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $502.1 million. On the bottom line, the average EPS estimate is $0.43.
Next year's average estimate for revenue is $2.03 billion. The average EPS estimate is $1.80.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 496 members out of 523 rating the stock outperform, and 27 members rating it underperform. Among 103 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 98 give Dr. Reddy's Laboratories a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Dr. Reddy's Laboratories is outperform, with an average price target of $33.70.
- Add Dr. Reddy's Laboratories to My Watchlist.
The article Dr. Reddy's Laboratories Increases Sales but Misses Estimates on Earnings originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend Dr. Reddy's Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.